A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus

被引:18
|
作者
Skaggs, Brian J. [1 ]
Grossman, Jennifer [1 ]
Sahakian, Lori [1 ]
Perry, Lucas [1 ]
FitzGerald, John [1 ]
Charles-Schoeman, Christina [1 ]
Gorn, Alan [1 ]
Taylor, Mihaela [1 ]
Moriarty, John [1 ]
Ragavendra, Nagesh [1 ]
Weisman, Michael [2 ]
Wallace, Daniel J. [1 ,2 ]
Hahn, Bevra H. [1 ]
McMahon, Maureen [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
基金
美国国家卫生研究院;
关键词
HIGH-DENSITY-LIPOPROTEINS; CONFER INCREASED RISK; C-REACTIVE PROTEIN; ACCELERATED ATHEROSCLEROSIS; PROGRESSION; PREVENTION; HDL; ATORVASTATIN; INFLAMMATION; PREVALENCE;
D O I
10.1002/acr2.11223
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The increase in cardiovascular events (CVEs) in systemic lupus erythematosus (SLE) is not fully explained by traditional risk factors. We previously identified four biomarkers (proinflammatory high-density lipoprotein, leptin, soluble TNF-like weak inducer of apoptosis (sTWEAK), and homocysteine) that we combined with age and diabetes to create the predictors of risk for elevated flares, damage progression, and increased cardiovascular diseasein patients with SLE (PREDICTS) risk profile. PREDICTS more accurately identified patients with SLE at risk for progression of subclinical atherosclerosis than any individual variable. We examined whether PREDICTS can also identify patients with SLE at risk for future CVEs. Methods A total of 342 patients with SLE and 155 matched control subjects participated in this longitudinal prospective study. A high PREDICTS score was defined as three or more predictors or diabetes + one or more predictor. The biomarkers were measured at baseline using published methods. All major adverse CVEs (MACEs) were confirmed by medical record review. Results During 116 months of follow-up, 5% of patients with SLE died, 12% had a cerebrovascular event, and 5% had a cardiac event. Overall, 20% of patients with lupus experienced any new MACE compared with 5% of control subjects (P < 0.0001). More patients with SLE with a new MACE had high PREDICTS score at baseline (77%) versus patients with no new events (34%) (P < 0.0001). High baseline PREDICTS score also associated with cerebrovascular (P < 0.0001) and cardiac events (P < 0.0001) in SLE. Using Cox regression, a baseline high PREDICTS score associated with a 3.7-fold increased hazard ratio (HR) for a new MACE (P < 0.0001) in SLE. Hypertension (HR = 2.1; P = 0.006) was also a risk. Conclusion A high PREDICTS score and hypertension confer increased risk for new MACEs in patients with SLE.
引用
收藏
页码:209 / 220
页数:12
相关论文
共 50 条
  • [1] A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus
    McMahon, Maureen
    Skaggs, Brian J.
    Grossman, Jennifer M.
    Sahakian, Lori
    FitzGerald, John
    Wong, Weng Kee
    Lourenco, Elaine V.
    Ragavendra, Nagesh
    Charles-Schoeman, Christina
    Gorn, Alan
    Karpouzas, George A.
    Taylor, Mihaela B.
    Watson, Karol E.
    Weisman, Michael H.
    Wallace, Daniel J.
    Hahn, Bevra H.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 (01) : 130 - 139
  • [2] The cardiovascular risk associates in systemic lupus erythematosus patients
    Dima, A.
    Balanescu, P.
    Delcea, C.
    Balanescu, E.
    Badea, C.
    Buzea, A.
    Ionescu, R.
    Baicus, C.
    Dan, G.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S80 - S80
  • [3] Sclerostin as a biomarker of cardiovascular risk in women with systemic lupus erythematosus
    Garcia-de los Rios, Carlos
    Medina-Casado, Marta
    Diaz-Chamorro, Antonio
    Sierras-Jimenez, Maria
    Lardelli-Claret, Pablo
    Caliz-Caliz, Rafael
    Sabio, Jose Mario
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01):
  • [4] Sclerostin as a biomarker of cardiovascular risk in women with systemic lupus erythematosus
    Carlos Garcia-de los Ríos
    Marta Medina-Casado
    Antonio Díaz-Chamorro
    María Sierras-Jiménez
    Pablo Lardelli-Claret
    Rafael Cáliz-Cáliz
    José Mario Sabio
    [J]. Scientific Reports, 12 (1)
  • [5] Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events
    Smilowitz, Nathaniel R.
    Katz, Gregory
    Buyon, Jill P.
    Clancy, Robert M.
    Berger, Jeffrey S.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 45 (01) : 13 - 17
  • [6] Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events
    Nathaniel R. Smilowitz
    Gregory Katz
    Jill P. Buyon
    Robert M. Clancy
    Jeffrey S. Berger
    [J]. Journal of Thrombosis and Thrombolysis, 2018, 45 : 13 - 17
  • [7] Cardiovascular events in patients with systemic lupus erythematosus
    Smrzova, Andrea
    Horak, Pavel
    Skacelova, Martina
    Zurek, Martin
    Frysakova, Ladislava
    Vymetal, Jiri
    Vaverkova, Helena
    [J]. COR ET VASA, 2014, 56 (02) : E145 - E152
  • [8] CARDIOVASCULAR RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Kechida, M.
    Jomaa, W.
    Mesfar, R.
    Daada, S.
    Klii, R.
    Hammami, S.
    Khochtali, I.
    [J]. ATHEROSCLEROSIS, 2019, 287 : E190 - E190
  • [9] Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
    Sivakumaran, Jagan
    Harvey, Paula
    Omar, Ahmed
    Tayer-Shifman, Oshrat
    Urowitz, Murray B.
    Gladman, Dafna D.
    Anderson, Nicole
    Su, Jiandong
    Touma, Zahi
    [J]. LUPUS SCIENCE & MEDICINE, 2021, 8 (01):
  • [10] Cardiovascular risk in systemic lupus erythematosus - evidence of increased oxidative stress and dyslipidaemia
    Nuttall, SL
    Heaton, S
    Piper, MK
    Martin, U
    Gordon, C
    [J]. RHEUMATOLOGY, 2003, 42 (06) : 758 - 762